If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


 
ARCH Venture Fund X, L.P.
 
Signature:ARCH Venture Partners X, L.P.
Name/Title:its General Partner
Date:11/09/2026
 
Signature:ARCH Venture Partners X, LLC
Name/Title:its General Partner
Date:11/09/2026
 
Signature:/s/ Mark McDonnell
Name/Title:Keith Crandell, Managing Director, by Mark McDonnell, Attorney-in-Fact
Date:11/09/2026
 
ARCH Venture Partners X, L.P.
 
Signature:ARCH Venture Partners X, LLC
Name/Title:its General Partner
Date:11/09/2026
 
Signature:/s/ Mark McDonnell
Name/Title:Keith Crandell, Managing Director, by Mark McDonnell, Attorney-in-Fact
Date:11/09/2026
 
ARCH Venture Fund X Overage, L.P.
 
Signature:ARCH Venture Partners X Overage, L.P.
Name/Title:its General Partner
Date:11/09/2026
 
Signature:ARCH Venture Partners X, LLC
Name/Title:its General Partner
Date:11/09/2026
 
Signature:/s/ Mark McDonnell
Name/Title:Keith Crandell, Managing Director, by Mark McDonnell, Attorney-in-Fact
Date:11/09/2026
 
ARCH Venture Partners X Overage, L.P.
 
Signature:ARCH Venture Partners X, LLC
Name/Title:its General Partner
Date:11/09/2026
 
Signature:/s/ Mark McDonnell
Name/Title:Keith Crandell, Managing Director, by Mark McDonnell, Attorney-in-Fact
Date:11/09/2026
 
ARCH Venture Partners X, LLC
 
Signature:/s/ Mark McDonnell
Name/Title:Keith Crandell, Managing Director, by Mark McDonnell, Attorney-in-Fact
Date:11/09/2026
 
ARCH Venture Fund XIV, L.P.
 
Signature:ARCH Venture Partners XIV, L.P.
Name/Title:its General Partner
Date:11/09/2026
 
Signature:ARCH Venture Partners XIV, LLC
Name/Title:its General Partner
Date:11/09/2026
 
Signature:/s/ Mark McDonnell
Name/Title:Keith Crandell, Managing Director, by Mark McDonnell, Attorney-in-Fact
Date:11/09/2026
 
ARCH Venture Partners XIV, L.P.
 
Signature:ARCH Venture Partners XIV, LLC
Name/Title:its General Partner
Date:11/09/2026
 
Signature:/s/ Mark McDonnell
Name/Title:Keith Crandell, Managing Director, by Mark McDonnell, Attorney-in-Fact
Date:11/09/2026
 
ARCH Venture Partners XIV, LLC
 
Signature:/s/ Mark McDonnell
Name/Title:Keith Crandell, Managing Director, by Mark McDonnell, Attorney-in-Fact
Date:11/09/2026
 
Robert Nelsen
 
Signature:/s/ Mark McDonnell
Name/Title:Mark McDonnell as Attorney-in-Fact for Robert Nelsen
Date:11/09/2026
 
Keith Crandell
 
Signature:/s/ Mark McDonnell
Name/Title:Mark McDonnell as Attorney-in-Fact for Keith Crandell
Date:11/09/2026
 
Kristina Burow
 
Signature:/s/ Mark McDonnell
Name/Title:Mark McDonnell as Attorney-in-Fact for Kristina Burow
Date:11/09/2026
 
Steven Gillis
 
Signature:/s/ Mark McDonnell
Name/Title:Mark McDonnell as Attorney-in-Fact for Steven Gillis
Date:11/09/2026
 
Paul Berns
 
Signature:/s/ Mark McDonnell
Name/Title:Mark McDonnell as Attorney-in-Fact for Paul Berns
Date:11/09/2026
EX-99.1

Exhibit 1

AGREEMENT

 

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of Aspen Neuroscience, Inc.

 

This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.

 

Dated: November 9, 2026

ARCH VENTURE FUND X, L.P.

 

By: ARCH Venture Partners X, L.P.

its General Partner

 

By: ARCH Venture Partners X, LLC

its General Partner

By: *

Keith Crandell

Managing Director

 

ARCH VENTURE PARTNERS X, L.P.

 

By: ARCH Venture Partners X, LLC

its General Partner

 

By: *

Keith Crandell

Managing Director

 

 

ARCH VENTURE FUND X OVERAGE, L.P.

 

By: ARCH Venture Partners X Overage, L.P.

its General Partner

 

By: ARCH Venture Partners X, LLC

its General Partner

By: *

Keith Crandell

Managing Director

 

ARCH VENTURE PARTNERS X OVERAGE, L.P.

 

By: ARCH Venture Partners X, LLC

its General Partner

 

By: *

Keith Crandell

Managing Director

 

ARCH VENTURE PARTNERS X, LLC

 

By: *

Keith Crandell

Managing Director

 

 

ARCH VENTURE FUND XIV, L.P.

 


By: ARCH Venture Partners XIV, L.P.

its General Partner

 

By: ARCH Venture Partners XIV, LLC

its General Partner

By: **

Keith Crandell

Managing Director

 

ARCH VENTURE PARTNERS XIV, L.P.

 

By: ARCH Venture Partners XIV, LLC

its General Partner

 

By: **

Keith Crandell

Managing Director

 

ARCH VENTURE PARTNERS XIV, LLC

 

By: **

Keith Crandell

Managing Director

 

 

*

Keith Crandell

 

*

Robert Nelsen

 

*

Kristina Burow

 

*

Steven Gillis

 

 

*

Paul Berns

 

* ** By: /s/ Mark McDonnell

Mark McDonnell as

Attorney-in-Fact

 

* This Agreement of Joint Filing was executed by Mark McDonnell pursuant to a Powers of Attorney filed as Exhibit 24 and 24.1 to the Form 3 relating to the beneficial ownership of shares of Prime Medicine, Inc. by the Reporting Persons filed with the Securities Exchange Commission on October 19, 2022 and incorporated herein in its entirety by reference.

 

** This Agreement of Joint Filing was executed by Mark McDonnell pursuant to a Power of Attorney.